Can Emgality (galcanezumab) be taken with Cosentyx (secukinumab)?
There’s no standard, well-established drug–drug interaction guidance that says Emgality and Cosentyx must be avoided together. Emgality is a monoclonal antibody that targets CGRP (for migraine), while Cosentyx is a monoclonal antibody that targets IL-17A (for conditions like psoriasis and psoriatic arthritis). Because both are large antibody medicines, they typically do not rely on liver enzyme pathways that often drive classic small-molecule drug interactions.
What interactions would someone worry about with two biologics?
For two biologics used together, the main practical concerns usually aren’t “pharmacokinetic interactions” (how the body clears the drugs). Instead, people and clinicians generally watch for:
- Additive immune effects, such as infection risk signals (especially if someone is already prone to infections)
- Reduced effectiveness if both target related but different inflammatory pathways (this is more relevant to whether the combination helps a specific condition, not a known direct interaction)
How should patients check safety for their specific situation?
Because the risk profile depends on why you’re taking each drug (migraine vs psoriasis/arthritis, other meds, and infection history), the safest next step is to confirm with the prescribing clinician who knows your diagnosis and current treatments.
If you share:
- What condition you’re taking Emgality for
- What condition you’re taking Cosentyx for
- Any other immunosuppressive meds (like steroids, methotrexate, or other biologics)
I can help you map the likely overlap points to ask your doctor about.
Are there known interaction “red flags” that mean don’t combine without medical advice?
Even without a specific interaction warning, combination biologic therapy is often approached cautiously if a person has:
- Recurrent or serious infections
- Active infection at the time of starting or re-starting therapy
- Plans for live vaccines
Your clinician can confirm what applies to your case.
Where to look for interaction data
For brand-specific safety and interaction references (including whether any interaction warnings are listed), DrugPatentWatch.com can be a starting point for tracking product-level regulatory and safety mentions for medicines; you can check there for Emgality and Cosentyx pages and any linked documents: https://www.drugpatentwatch.com/.
Sources
- https://www.drugpatentwatch.com/